65,437 trials
Gingivitis
Primary: Mean Interproximal Lobene Modified Gingival Index Between the Brushing Only Group and the Brushing + Flossing Group — 2.11; 1.87 units on a scale — p=0.001
Familial Mediterranean Fever
Primary: To Assess the Efficacy of Rilonacept in Decreasing the Number of Acute FMF Attacks. — 0.77; 2.00 number of attacks per month — p=0.027
Ascites · Cirrhosis
Primary: Score Out of Total Possible 25 on a Likert Scale. — 21; 21; 20 units on a Likert scale (maximum is 25)
Breast Cancer
Primary: Overall Survival — 83; 79; 79 percentage of patients alive
Anaplastic Astrocytoma · Glioblastoma
Primary: Number of Participants With Progression Free Survival (PFS) at 6 Months Utilizing McDonald Criteria for Response, Progression and Relapse — 4; 2; 2 Participants
Type 1 Diabetes Mellitus
Primary: C-peptide Area Under the Curve (AUC) Response to a Mixed Meal Tolerance Test (MMTT) at 12 Months — 0.451; 0.371 pmol/ml
Perennial Allergic Rhinitis
Primary: Treatment Satisfaction Subscales (Interference, Regimen Adaptation, Role Limitations, Sensory Impact, Regimen Difficulties, Burden, Hassle, Regimen Management, and…
Hypertension
Primary: Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure (MASBP) at Week 8 — -15.3; -11.5 mmHg
Mycosis Fungoides
Primary: Ratio of Response Rates Based on CAILS — 76; 62 percentage of participants
Myopia
Primary: Mean Value of Comfort During the Day — 89; 85; 86 Units on a scale
Pulmonary Arterial Hypertension
Primary: Change From Baseline in 6-Minute Walk Distance (6MWD) at Year 1 — 29.4 meter
Primary Open Angle Glaucoma
Primary: Change in Intraocular Pressure at 60 Minutes — 1.51; 0.52 mm Hg
Neoplasms
Primary: Number of Participants With First Cycle Dose Limiting Toxicities (DLTs) — 0; 1; 0; 0 participants
Asthma
Primary: Forced Expiratory Volume in One Second (FEV1) Area Under the Curve 0-24 Hours (AUC0-24h) Response — 0.091; 0.241; 0.250 L — p=<0.0001
Asthma
Primary: Total Number of Asthma Exacerbations — 36; 61 Exacerbations